Related Experiment Video

Updated: May 11, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Targeting PI3K in Cancer: Any Good News?

Miriam Martini1, Elisa Ciraolo, Federico Gulluni

  • 1Molecular Biotechnology Center, University of Turin Turin, Italy.

Frontiers in Oncology
|May 10, 2013
PubMed

Insights

Targeted therapies for cancer, including PI3K inhibitors, are advancing. Identifying specific PIK3CA mutations helps predict patient response to these treatments for personalized cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The phosphatidylinositol 3-kinase (PI3K) signaling pathway is crucial for cellular functions and frequently dysregulated in human cancers.
  • Targeting the PI3K pathway is a key strategy in cancer drug development, with various inhibitors (PI3K, AKT, mTOR, dual PI3K/mTOR) in clinical trials.

Purpose of the Study:

  • To review the role of individual PIK3CA mutations in predicting sensitivity and resistance to PI3K pathway inhibitors.
  • To highlight the importance of patient stratification for personalized cancer treatment strategies involving novel PI3K/mTOR/AKT inhibitors.

Main Methods:

  • Literature review of preclinical and clinical studies on PI3K pathway inhibitors.
  • Analysis of PIK3CA mutation data in relation to treatment response.
  • Discussion of emerging targeted therapies and personalized medicine approaches.

Main Results:

  • Specific PIK3CA mutations are emerging as important biomarkers for predicting response to PI3K pathway inhibitors.
  • Understanding mutation-specific sensitivity and resistance is critical for effective clinical trial design and patient selection.
  • Novel PI3K/mTOR/AKT inhibitors offer potential for more tailored cancer treatments.

Conclusions:

  • PIK3CA mutation status is a key determinant of response to PI3K pathway-targeted therapies.
  • Personalized treatment strategies incorporating PIK3CA mutation analysis will improve outcomes for cancer patients.
  • Further research is needed to fully elucidate the complex interplay between PIK3CA mutations and targeted therapies.
Keywords:
PI3Kcancerclass II phosphatidylinositol 3-kinasegenetic determinantstherapeutics

More Related Videos

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...